Guangjing Wang,Chengcheng Shi,Xiaofeng Xu,Yuan Zhang,Zhanfa Sun. High level of preoperative serum fibrinogen is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Transl Med, 2020, 6: 228-232.
High level of preoperative serum fibrinogen is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma
Received:May 24, 2020  Revised:October 16, 2020
View Full Text  View/Add Comment  Download reader
KeyWord:esophageal squamous cell carcinoma; biomarker; prognosis; serum fibrinogen
Author NameAffiliationE-mail
Guangjing Wang Department of Cardiothoracic Surgery, Qingdao Municipal Hospital gjwang123@aliyun.com 
Chengcheng Shi Department of Cardiothoracic Surgery, Qingdao Municipal Hospital  
Xiaofeng Xu Department of Cardiothoracic Surgery, Qingdao Municipal Hospital  
Yuan Zhang Department of Cardiothoracic Surgery, Qingdao Municipal Hospital  
Zhanfa Sun Department of Cardiothoracic Surgery, Qingdao Municipal Hospital  
Hits: 6928
Download times: 7736
Abstract:
      Objective This study aimed to elucidate the association between the level of preoperative serum fibrinogen (PSF) and the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Methods From January 2010 to December 2016, all patients diagnosed with ESCC who underwent surgery in Qingdao Municipal Hospital were analyzed retrospectively. Moreover, the fibrinogen levels of all patients were assessed before surgery, and hyperfibrinogenemia was diagnosed when the fibrinogen level was ≥4.0 g/L. The impact of PSF on disease-free survival (DFS) and overall survival (OS) was analyzed using the log-rank method and Cox proportional hazards regression model. P value less than 0.05 was considered statistically significant. Results A total of 336 patients were finally analyzed, and approximately 102 patients (30.36%) were diagnosed with hyperfibrinogenemia before surgery. Hyperfibrinogenemia was associated with older age (≥ 70 years) (P = 0.012), advanced pathological T stage (P = 0.003), and lymph node involvement (P = 0.024). Univariate analysis showed that patients with hyperfibrinogenemia had shorter DFS (1.96 years vs. 3.64 years, P = 0.001) and OS (2.27 years vs. 4.15 years, P < 0.001) than patients without hyperfibrinogenemia. Multivariate analysis confirmed that PSF was an independent factor affecting DFS (risk ratio [RR]: 1.35, 95% confidence interval [CI]: 1.02–1.79, P = 0.038) and OS (RR: 1.37, 95% CI: 1.03–1.83, P = 0.034) in patients with ESCC. Conclusion For patients with operable ESCC, hyperfibrinogenemia had poor prognosis. Moreover, PSF is an independent prognostic factor for operable ESCC.
Close